Mela Sciences Inc (MELA)

1.69
0.03 1.74
NASDAQ : Health Care
Prev Close 1.72
Open 1.75
Day Low/High 1.67 / 1.75
52 Wk Low/High 0.51 / 1.53
Volume 4.50K
Avg Volume 33.30K
Exchange NASDAQ
Shares Outstanding 10.18M
Market Cap 11.41M
EPS -3.03
P/E Ratio N/A
Div & Yield N.A. (N.A)
MELA Sciences Announces New Study Results Demonstrating Improved Diagnostic Accuracy For Resident Dermatologists When Utilizing MelaFind Predictive Probability Information

MELA Sciences Announces New Study Results Demonstrating Improved Diagnostic Accuracy For Resident Dermatologists When Utilizing MelaFind Predictive Probability Information

Results to be Presented at Practical Dermatology & Dermatopathology Symposium August 14-17

MELA Sciences Initiates First Study To Investigate Real-World Clinical Impact Of The MelaFind System On Melanoma Biopsy Decision

MELA Sciences Initiates First Study To Investigate Real-World Clinical Impact Of The MelaFind System On Melanoma Biopsy Decision

Darrell Rigel of NYU School of Medicine Named Principal Investigator

MELA Sciences Secures Final Investigative Site And Enrolls 100+ Patients For Post-Approval Study For MelaFind® System Optical Melanoma Diagnostic Device

MELA Sciences Secures Final Investigative Site And Enrolls 100+ Patients For Post-Approval Study For MelaFind® System Optical Melanoma Diagnostic Device

MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind ® system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced that it has concluded an...

Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook As CFO

Medical Diagnostic Developer MELA Sciences Appoints Senior Healthcare Finance Executive Robert W. Cook As CFO

MELA Sciences, Inc. (NASDAQ:MELA), developer of the MelaFind ® system, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, appointed veteran healthcare executive...

MELA Sciences Announces 2013 Fourth Quarter And Year-End Financial Results

MELA Sciences Announces 2013 Fourth Quarter And Year-End Financial Results

MELA Sciences, Inc. (NASDAQ:MELA), (the “Company”), developer of MelaFind ®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced financial...

Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, As Director

Optical Diagnostic Developer, MELA Sciences, Appoints Veteran Medical Device Investment Banker, Samuel Navarro, As Director

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind ®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the appointment of veteran medical ...

Dermatology Diagnostic Developer, MELA Sciences, To Host Q4 Conference Call Monday, March 17, 2014 At 4:30 Pm ET

Dermatology Diagnostic Developer, MELA Sciences, To Host Q4 Conference Call Monday, March 17, 2014 At 4:30 Pm ET

MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind ®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, will release its fourth quarter and full year 2013 results...

Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension To Meet NASDAQ Minimum Bid Price

Melanoma Diagnostic Provider, MELA Sciences Receives 180-Day Extension To Meet NASDAQ Minimum Bid Price

MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, has filed a Form 8-K providing full details of a ...

MELA Sciences Completes Private Placement To Institutional Investors And MELA Sciences Directors

MELA Sciences Completes Private Placement To Institutional Investors And MELA Sciences Directors

MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today announced the closing of its previously ...

Melanoma Diagnostic Provider, MELA Sciences Provides Details Of Recent $12.45 Million Private Placement

Melanoma Diagnostic Provider, MELA Sciences Provides Details Of Recent $12.45 Million Private Placement

MELA Sciences, Inc. (NASDAQ:MELA), (the Company) developer of MelaFind®, an FDA approved optical diagnostic device that assists dermatologists in melanoma diagnosis, today filed a Form 8-K providing full details from ...

Dermatologist Highlights Medical Benefits Of MelaFind Device In Aiding Melanoma Diagnosis At Most Treatable Stage

Dermatologist Highlights Medical Benefits Of MelaFind Device In Aiding Melanoma Diagnosis At Most Treatable Stage

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind ® , an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, hosted a MelaFind ® workshop during the...

Medical Diagnostic Developer MELA Sciences To Present At SeeThruEquity Microcap Conf. Feb. 6 In NYC And To Exhibit At Maui Dermatology Conf. Jan. 26-30

Medical Diagnostic Developer MELA Sciences To Present At SeeThruEquity Microcap Conf. Feb. 6 In NYC And To Exhibit At Maui Dermatology Conf. Jan. 26-30

MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind ®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced its CEO, Rose Crane, will present at...

MELA Sciences Announces The Results Of Its Third Clinical Advisory Meeting And The Four Clinical Posters Presented At The Winter Clinical Dermatology Conference

MELA Sciences Announces The Results Of Its Third Clinical Advisory Meeting And The Four Clinical Posters Presented At The Winter Clinical Dermatology Conference

MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind ®, an FDA approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, today announced the results of its third ...

Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters At Winter Clinical Dermatology Conference - January 17 - 22

Melanoma Diagnostic Developer MELA Sciences Hosts Clinical Advisory Meeting & Exhibits Four Clinical Posters At Winter Clinical Dermatology Conference - January 17 - 22

MELA Sciences, Inc. (NASDAQ:MELA), developer of MelaFind ®, an FDA-approved optical diagnostic device that assists dermatologists in the diagnosis of melanoma, will host its third company-sponsored ...

MELA Sciences Reports Positive Reception For Its Optical Melanoma Diagnostic Device At Clinical Advisory Meeting And Mount Sinai Winter Dermatology Symposium

MELA Sciences Reports Positive Reception For Its Optical Melanoma Diagnostic Device At Clinical Advisory Meeting And Mount Sinai Winter Dermatology Symposium

MELA Sciences, Inc. (NASDAQ: MELA) designer and developer of MelaFind ®, an FDA approved non-invasive optical device that assists dermatologists in the diagnosis of melanoma, received positive dermatologist...

Melanoma Diagnostics Leader, MELA Sciences, Inc., Participates In Skin Cancer Diagnostic Workshop With Leading German Dermatologists, Hosted By Germany’s Augsburg Clinic

Melanoma Diagnostics Leader, MELA Sciences, Inc., Participates In Skin Cancer Diagnostic Workshop With Leading German Dermatologists, Hosted By Germany’s Augsburg Clinic

MELA Sciences, Inc. (NASDAQ:MELA), designer and developer of MelaFind ®, an FDA and CE Mark approved non-invasive optical device that assists dermatologists in diagnosing melanoma at its most curable stage, ...

New Data Presented At The Fall Clinical Dermatology Conference Supports MelaFind(R) As A Fundamental Tool For Dermatologists

New Data Presented At The Fall Clinical Dermatology Conference Supports MelaFind(R) As A Fundamental Tool For Dermatologists

Leading Dermatologists Presented Findings in Four Poster Presentations at the 32nd Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada

MELA Sciences, Inc. To Participate In The Fall Clinical Dermatology Conference

MELA Sciences, Inc. To Participate In The Fall Clinical Dermatology Conference

Leading Dermatologists to Present Clinical Findings in Four Poster Presentations at the 32nd Annual Fall Clinical Dermatology Conference in Las Vegas, Nevada